Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Guardant Health, Inc.GH · Entity 3238 | Director · Co-Chief Executive Officer | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Guardant Health, Inc.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,943,751 |
Reported balance
After 2026-09-30 transaction · row 1
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 1 · 2026-09-30 · Exercise / conversion · Acquired 2,817 · Balance 1,943,751 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,942,323 |
Reported balance
After 2026-09-30 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-09-30 · Tax withholding · Disposed 1,428 · Balance 1,942,323 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,966,320 |
Reported balance
After 2026-10-01 transaction · row 3
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 3 · 2026-10-01 · Exercise / conversion · Acquired 23,997 · Balance 1,966,320 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,976,036 |
Reported balance
After 2026-10-01 transaction · row 4
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 4 · 2026-10-01 · Exercise / conversion · Acquired 9,716 · Balance 1,976,036 |
| Common StockSEC Table I · non-derivative | IndirectShares held by Helmy A. Eltoukhy Revocable Trust | 1,958,949 |
Reported balance
After 2026-10-01 transaction · row 5
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 5 · 2026-10-01 · Tax withholding · Disposed 17,087 · Balance 1,958,949 F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 2,817 |
Reported balance
After 2026-09-30 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2026-09-30 · Exercise / conversion · Disposed 2,817 · Balance 2,817 F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 23,998 |
Reported balance
After 2026-10-01 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-10-01 · Exercise / conversion · Disposed 23,997 · Balance 23,998 F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 48,580 |
Reported balance
After 2026-10-01 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2026-10-01 · Exercise / conversion · Disposed 9,716 · Balance 48,580 F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter. F3: Not applicable for Restricted Stock Units. |
Filing footnotes · ownership attribution and instrument terms
F1: These shares were retained by the Company in order to meet the tax withholding obligations of the award-holder in connection with the vesting of an installment of the restricted stock units. The amount retained by the Company was not in excess of the amount of the tax liability.
F2: This represents a restricted stock unit award granted on March 17, 2026 that vests in four equal installments on the last day of each calendar quarter, March 31, 2026, June 30, 2026, September 30, 2026, and December 31, 2026.
F3: Not applicable for Restricted Stock Units.
F4: This represents a restricted stock unit award granted on March 18, 2024 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2025 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
F5: This represents a restricted stock unit award granted on March 12, 2025 that vests over a three-year period. 33% of the shares subject to such award vested on January 1, 2026 and the remaining 67% of the shares vests in equal quarterly installments over the remaining two-year period thereafter.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 15, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 29,785 | $103.30 | $3,076,653.49 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,250,197 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $102.70 to $103.695, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 37,474 | $102.21 | $3,830,195.06 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,279,982 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $101.70 to $102.68, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| September 15, 2020 Filed Sep 18, 2020 01:10 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 22,926 | $4.18 | $95,830.68 |
DisclosureSEC source: 0001628280-20-013721 · wf-form4_160039142031045.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,317,456 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 26, 2020 Filed May 28, 2020 00:50 UTC | Guardant Health, Inc. GH · Entity 3238 | GrantPerformance-Based Restricted Stock Units · Derivative | 1,695,574 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-008487 · wf-form4_159062698434178.xml · derivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,695,574 Underlying: COMMON STOCK · 1,695,574 shares Expires 2027-05-26 F1 · derivative.exercise_price: Each performance-based restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: The performance-based restricted stock units vest, if at all, based on the Issuer's achievement of certain stock price milestones. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 21:17 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 100 | $71.21 | $7,121.02 |
DisclosureSEC source: 0001628280-20-005205 · wf-form4_158750385593612.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,174,980 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $71.04 to $71.245, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 17, 2020 Filed Apr 21, 2020 21:17 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 15,804 | $70.21 | $1,109,617.80 |
DisclosureSEC source: 0001628280-20-005205 · wf-form4_158750385593612.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,175,080 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $70.00 to $70.60, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 16, 2020 Filed Apr 16, 2020 21:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 200 | $70.01 | $14,001.00 |
DisclosureSEC source: 0001628280-20-005073 · wf-form4_158707371283840.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,190,884 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $70.00 to $70.01, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| April 14, 2020 Filed Apr 16, 2020 21:48 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,701 | $70.06 | $189,241.24 |
DisclosureSEC source: 0001628280-20-005073 · wf-form4_158707371283840.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,191,084 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $70.00 to $70.28, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 20:58 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 24,593 | $71.12 | $1,748,987.76 |
DisclosureSEC source: 0001628280-20-004468 · wf-form4_158577467929960.xml · nonDerivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,193,785 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F8 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $71.00 to $71.26, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 31, 2020 Filed Apr 1, 2020 20:58 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 78,510 | $70.61 | $5,543,426.23 |
DisclosureSEC source: 0001628280-20-004468 · wf-form4_158577467929960.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,218,378 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F7 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $70.00 to $70.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 20:58 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 31,916 | $70.92 | $2,263,613.58 |
DisclosureSEC source: 0001628280-20-004468 · wf-form4_158577467929960.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,296,888 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F6 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $70.64 to $71.30, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 20:58 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 80,167 | $70.30 | $5,635,732.08 |
DisclosureSEC source: 0001628280-20-004468 · wf-form4_158577467929960.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,328,804 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F5 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $69.54 to $70.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 20:58 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 46,310 | $69.04 | $3,197,140.52 |
DisclosureSEC source: 0001628280-20-004468 · wf-form4_158577467929960.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,408,971 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F4 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $68.54 to $69.53, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 20:58 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 16,900 | $68.20 | $1,152,618.87 |
DisclosureSEC source: 0001628280-20-004468 · wf-form4_158577467929960.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,455,281 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F3 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $67.53 to $68.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 20:58 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,800 | $67.00 | $187,587.96 |
DisclosureSEC source: 0001628280-20-004468 · wf-form4_158577467929960.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,472,181 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is a weighted average price.The shares were sold in multiple transactions at prices ranging from $66.53 to $67.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| November 26, 2019 Filed Feb 5, 2020 21:26 UTC | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 120,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-001095 · wf-form5_158093798370596.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,476,334 F1 · kind: Represents shares of Common Stock that the Reporting Person donated as a gift to a donor advised fund administered by Vanguard Charitable. Read SEC document |
| November 07, 2019 Filed Feb 11, 2020 21:12 UTC Amendment | Guardant Health, Inc. GH · Entity 3238 | GiftCOMMON STOCK | 1,353 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-20-001352 · wf-form5a_158145555186866.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,474,981 F1 · ownership.direct: Ownership as of December 31, 2019. F2 · ownership.direct: The Reporting Person does not serve as a trustee or exercise any control over the securities held by the Genevieve Eltoukhy 2018 Irrevocable Trust, the Isabella Eltoukhy 2018 Irrevocable Trust or the Camille Eltoukhy 2018 Irrevocable Trust, and thus, the Reporting Person is not deemed to indirectly hold such securities. Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 22:54 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 71,769 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-011603 · wf-form4_156815606531851.xml · derivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 884,458 Underlying: COMMON STOCK · 71,769 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017 Read SEC document |
| September 06, 2019 Filed Sep 10, 2019 22:54 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 71,769 | $4.18 | $299,994.42 |
DisclosureSEC source: 0001628280-19-011603 · wf-form4_156815606531851.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,596,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 16, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 53,150 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · derivative · entry 21 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 956,227 Underlying: COMMON STOCK · 53,150 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| August 16, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 10,434 | $101.66 | $1,060,720.44 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 16 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,524,565 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F14 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.58 to $101.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 133,534 | $101.18 | $13,510,970.12 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 15 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,534,999 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.56 to $101.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 22,127 | $100.40 | $2,221,550.80 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 14 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,668,533 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.56 to $100.55, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 16, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 53,150 | $4.18 | $222,167.00 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 13 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,690,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 8,428 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · derivative · entry 20 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,009,377 Underlying: COMMON STOCK · 8,428 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 892 | $99.10 | $88,397.20 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 12 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,637,510 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.05 to $99.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 19,040 | $98.74 | $1,880,009.60 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 11 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,638,402 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.05 to $99.00, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,404 | $97.80 | $626,311.20 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 10 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,657,442 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.05 to $98.04, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 15, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 8,428 | $4.18 | $35,229.04 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 9 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,663,846 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 19,606 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · derivative · entry 19 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,017,805 Underlying: COMMON STOCK · 19,606 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F15 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 200 | $101.42 | $20,284.00 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 8 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,655,418 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.33 to $101.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 12,300 | $100.67 | $1,238,241.00 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,655,618 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.80 to $100.75, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 20,321 | $99.12 | $2,014,217.52 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,667,918 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.80 to $99.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 13,704 | $98.23 | $1,346,143.92 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,688,239 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.78 to $98.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 3,921 | $97.20 | $381,121.20 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 4 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,701,943 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.77 to $97.71, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 6,107 | $95.91 | $585,722.37 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 3 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,705,864 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F3 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $95.59 to $96.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 4,715 | $95.07 | $448,255.05 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 2 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,711,971 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $94.56 to $95.54, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 14, 2019 Filed Aug 16, 2019 22:50 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 19,606 | $4.18 | $81,953.08 |
DisclosureSEC source: 0001628280-19-010908 · wf-form4_156599581412425.xml · nonDerivative · entry 1 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,716,686 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 98,307 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · derivative · entry 18 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,037,411 Underlying: COMMON STOCK · 98,307 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 606 | $101.30 | $61,387.80 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 14 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,697,080 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F13 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.26 to $101.34, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 89,416 | $100.75 | $9,008,662.00 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 13 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,697,686 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F12 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.26 to $101.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 158,529 | $99.83 | $15,825,950.07 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 12 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,787,102 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F11 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.26 to $100.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 44,446 | $98.96 | $4,398,376.16 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 11 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,945,631 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F10 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $98.26 to $99.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 11,813 | $97.83 | $1,155,665.79 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 10 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,990,077 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F9 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $97.26 to $98.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 2,400 | $96.79 | $232,296.00 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 9 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,001,890 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F8 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $96.24 to $97.15, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 13, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionCOMMON STOCK | 98,307 | $4.18 | $410,923.26 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 8 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,004,290 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | Exercise / conversionSTOCK OPTION (RIGHT TO BUY) · Derivative | 38,109 | $0.00 Strike: $4.18 | $0.00 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · derivative · entry 17 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,135,718 Underlying: COMMON STOCK · 38,109 shares Expires 2022-07-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F14 · derivative.exercise_date: The stock option vests and becomes exercisable in equal monthly installments over 48 months commencing on April 23, 2017. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 140 | $101.19 | $14,166.60 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 7 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,905,983 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F7 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $101.16 to $101.25, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 273 | $100.29 | $27,379.17 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 6 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,906,123 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F6 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $100.05 to $101.02, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 12, 2019 Filed Aug 14, 2019 23:13 UTC | Guardant Health, Inc. GH · Entity 3238 | SaleCOMMON STOCK | 51,254 | $99.58 | $5,103,873.32 |
DisclosureSEC source: 0001628280-19-010785 · wf-form4_156582438647240.xml · nonDerivative · entry 5 Eltoukhy Helmy · CIK 0001752968 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,906,396 F1 · shares: These shares were sold under a pre-arranged sales plan pursuant to Rule 10b5-1 under the Securities Exchange Act of 1934, as amended. Some of the shares sold were acquired contemporaneously upon the cashless exercise of stock options at an exercise price of $4.18 per share. F5 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $99.05 to $100.03, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.